PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Craig A. Coburn

Serial No.:

To Be Assigned

Case No.: 21455YP

US Nat'l Filing Date:

December 19, 2005

Int'l Appl'n No.

PCT/US2004/020234

Int'l Filing Date:

25 June 2004

For:

N-ALKYL PHENYLCARBOXAMIDE BETA-SECRETASE

INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S

DISEASE

Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR § 1.97**

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT EXPRESS MAIL NO.

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed

Commissioner for Patents, P. O. Box 1450, Alexandria, Virginia 22313-1450

10/563538

US Appl'n No.: Case No.: Page To Be Assigned 21455Y

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

IAP6 Rec'd PCT/PTO 19 DEC 2005

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement

Reference C (WO 03/057721) was cited in the International Search Report during the International phase of this application. A copy of the International Search Report and Written Opinion are also enclosed.

shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

John C. Todaro, Reg. No. 36,036 Attorney for Applicant

MERCK & CO., Inc. P.O. Box 2000 Rahway, New Jersey 07065-0907 (732) 594-0125

Date: December 19, 2005

IAP6 Rec'd PCT/PTO 19 DEC 2005
SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Su	Substitute for form 1449A/PTO			COMPLETE IF KNOWN			
	NFORMATION 1	DIS	CLOSURE	Application Number	To Be Assigned / 563538		
C	TEATED AT DATE	A TO		Filing Date	December 19, 2005		
3	TATEMENT BY	AP	PLICANI	First Named Inventor	Craig A. Coburn et al.		
			,	Group Art Unit	To Be Assigned		
	(use as many sheets	as n	necessary)	Examiner Name	To Be Assigned		
Sheet	1	of	2	Attorney Docket Number	21455Y		

			U.S. PATEN	NT DOCUMENTS		
Cuaminar	Cite No.	U.S. Patent Document			Date of Publication of	
Examiner Initials*		Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	

			FOREIG	N PATENT	T DOCUMENTS	
Examiner Initials*	Cite No.	Foreign Patent Document Office Number Kind Code (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	A		WO 89/04833	PCT	The Upjohn Company	06/01/1989
	В		WO 01/00665	PCT	Oklahoma Medical Research Foundation &	01/04/2001
					The Board of Trustees of the	
					University of Illinois	
	С		WO 03/057721	PCT	Elan Pharmaceuticals, Inc. &	07/17/2003
					Pharmacia & Upjohn Company	
						-

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LAP6 Rec'd PCT/PTO 19 UEL LUUJ
Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

<u> </u>	Substitute for form 1449B/PTO			COMPLETE IF KNOWN			
	NFORMATION]	DIS	CLOSURE	Application Number	то в да		
C	TO A TOTAL MITCHING TO NO.	A D	DI ICANIT	Filing Date	December 19, 2005		
.	STATEMENT BY APPLICANT			First Named Inventor	Craig A. Coburn et al.		
		•	,	Group Art Unit	To Be Assigned		
	(use as many sheets	as n	ecessary)	Examiner Name	To Be Assigned		
Sheet	2	of	2	Attorney Docket Number	21455Y		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
	AA	C. A. Coburn et al., "Identification of a Small Molecule Nonpeptide Active Site Beta-Secretase Inhibitor That Displays a Nontraditional Binding Mode for Aspartyl Proteases," J. Med. Chemistry, Vol. 47, pp. 6117-6119 (2004)				
1						

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.